Xconomy

DECEMBER 20, 2018

New biopharma company Aristea Therapeutics has raised $15 million from Novo Holdings, the Danish investment company, and secured global rights to an investigational AstraZeneca drug that’s ready for Phase 2 study. The San Diego, CA, company made its public debut this week after starting up quietly earlier this year.

Develop 67

Develop Development San Diego Study 67

Xconomy

JULY 6, 2016

The Obama administration’s push to sign up one million Americans for a long-term health study will start in New York, Pittsburgh, Chicago, and Tucson, AZ, top health officials said today. The VA is running its own long-term study with nearly half a million participants so far.).

Study 59

Study PMI San Diego Sample 59

Xconomy

FEBRUARY 26, 2020

About three years ago fledgling San Diego-based startup PvP Biologics announced a $35 million deal with Takeda Pharmaceutical that gave the Japan pharma giant rights to acquire the company down the line. The deal follows completion of a Phase 1 study evaluating the PvP drug. That day is here.

San Diego 72

San Diego Study Develop Development 72

Xconomy

OCTOBER 1, 2018

VelosBio, a biotech startup researching new cancer drugs, has raised $58 million in financing. VelosBio joined Johnson & Johnson’s JLABS @ San Diego incubator in January. The new VelosBio cash is earmarked for completing the work needed to proceed into human studies. The specific cancers that VelosBio.

San Diego 91

San Diego Incubator Class Study 91

Xconomy

APRIL 18, 2018

John Dobak, a life sciences serial entrepreneur in San Diego, said a new startup he’s leading has raised $2.66 The biotech, 10xBio, announced earlier this month that the FDA had approved its application to begin clinical trials in Phase 1b/2a studies testing the unnamed injectable drug.

San Diego 72

San Diego Study Entrepreneur Startup 72

Xconomy

APRIL 11, 2017

As part of the financing, Kalamazoo-based Octeta Therapeutics has been rechristened Cirius Therapeutics, and three San Diego-based biotech executives are stepping into key executive roles. All three were former Laguna Pharmaceuticals executives who spent the past 16 months scouting for Frazier as entrepreneurs-in-residence.

Study 55

Study San Diego Entrepreneur Venture Capital 55

Xconomy

NOVEMBER 27, 2018

Roche is acquiring San Diego startup Jecure Therapeutics, with hopes of turning Jecure’s early research into a drug or drugs that treat the liver disease NASH.

San Diego 67

San Diego Study Research Organization 67

Xconomy

NOVEMBER 2, 2018

The gene-editing technology CRISPR-Cas9 is opening up new research avenues all the time, such as giving drug developers a cheaper, faster way to knock out genes in tumor cells. Studies of CRISPR-Cas9 to treat human disease are about to start, too. This week, we reported on a new study that raises exactly that question.

Study 74

Study Startup Research Report 74

Xconomy

SEPTEMBER 25, 2017

After launching a study to identify how tech hubs work, the leader of a nonprofit consortium created to boost Southern California’s startup ecosystem says he is focusing on three initiatives to supercharge the seven-county SoCal region as a hotbed for innovation. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Southern California 61

Southern California San Diego SoCal Incubator 61

Xconomy

NOVEMBER 3, 2017

Plante is a technology industry veteran in San Diego who has served as the CEO of Bel-Tronics, and as the founding CEO of SmartDrive Systems and Pathway Genomics. Studies in mice have. Thynk Capital founder and principal Jim Plante also is Klotho’s founder and CEO.

San Diego 85

San Diego Study Capital Technology 85

Xconomy

FEBRUARY 15, 2017

For these reasons, fatty liver disease is often called a “silent disease,” says Ariel Feldstein, a gastroenterologist at the University of California San Diego. Feldstein has been studying the liver for nearly 20 years, and his research now forms the basis of a newly launched company called Jecure Therapeutics.

UCSD 64

UCSD Press San Diego Class 64

Xconomy

AUGUST 11, 2016

government has ambitious plans for a long-term health study with one million Americans, and one of the world’s most powerful tech companies has a big part to play, including the storage of all the data on its “cloud” servers. Vanderbilt had a head start stumping for it.

PMI 40

PMI Study Google Research 40

Xconomy

MAY 25, 2017

volunteers and amass a treasure trove of their health information will start next week with a “beta test” that health officials hope to eventually expand nationwide. An ambitious plan to recruit 1 million U.S. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Study 81

Study Startup San Diego Conference 81

Xconomy

AUGUST 22, 2016

In downtown San Diego, a private real estate company best known for its master-planned communities in suburban Southern California has posed some existential questions for regional tech hubs looking to build their own startup ecosystems. 101 West Broadway tower in downtown San Diego.

Develop 40

Develop Development San Diego Startup 40

Xconomy

FEBRUARY 15, 2017

At the UC San Diego Design Lab , director Don Norman talks about the importance of studying and understanding how people are actually using something—whether it is a computerized interface or a door handle. Here at Xconomy, we are gathering prominent scientists, executives, investors, and others in San Diego.

San Diego 64

San Diego Design Study Ideas 64

Xconomy

OCTOBER 22, 2018

Early next year, twenty students will have the opportunity to study machine learning for 10 weeks with Google engineers, college professors, and coaches—free of charge.

Course 94

Course Artificial Inteligence Google Coach 94

Both Sides of the Table

APRIL 13, 2011

Huge thank you to Steve De Long for the write up. I owe ya’ a 20 minute call (or in person next time I’m in San Diego). Brad on blogging. How did you start blogging? “My In 2004 / 2005 I was starting to get intrigued with user-generated content. was starting.

Venture Capital 288

Venture Capital Startup Technical Review Software Review 288

Xconomy

AUGUST 1, 2017

Ciara Kennedy, who succeeded Mike Grey as Amplyx CEO late last year, said in an interview with Xconomy that the company plans to report results of its Phase 1 study at IDWeek, the annual infectious diseases conference that is set for early October in San Diego. But raising $67.

San Diego 67

San Diego Study Conference Report 67

Xconomy

DECEMBER 7, 2017

Proceeds will be used to advance Metacrine’s lead drug candidate, MET409, into first-in-human studies during the first half of 2018. Initial studies should be completed by the end of the year, the San Diego-based company said.

San Diego 49

San Diego Study Develop Development 49

Xconomy

SEPTEMBER 27, 2016

Fortis Therapeutics, a new San Diego biotech, has raised $18 million in initial funding to develop drugs for hard-to-treat prostate and bone marrow cancers. San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups).

Avalon 40

Avalon Funding Startup San Diego 40

Xconomy

JUNE 21, 2018

The San Francisco company priced its IPO late Tuesday, selling 6.25 Eidos will use the cash to fund studies of AG10 , a drug in mid-stage testing for transthyretin (TTR) amyloidosis, a progressive and fatal condition caused by the. million shares at $17 each, which was on the high end of its projected $15 to $17 range.

Study 72

Study Startup Pricing Funding 72

Xconomy

MAY 30, 2016

Lita Nelsen has seen it up close—and played a part in its evolution—from her studies there in the 1960s, to her business-school fellowship in the late 1970s, to her 30 years working in MIT’s Technology Licensing Office. And so that’s what Stanford did, so it was set up in that model. That meant we were licensing.

Startup 67

Startup Compton Research Technology 67

Xconomy

MARCH 2, 2017

Time is running out to secure the $99 super saver discount for The Xconomy Forum on Human Impact of Innovation on April 19 in San Diego. There has been a lot of talk around the importance of studying and understanding how people use something—and we are bringing this idea front and center.

San Diego 40

San Diego Study Ideas Artificial Inteligence 40

Xconomy

APRIL 22, 2020

The start of a potentially big biomedical breakthrough is blooming within all of us. Drug research aiming to turn bacteria into microbiome therapies now spans programs aiming to address gut disorders, autism, cancer, and more.

Class 138

Class Study Research Report 138

Xconomy

JUNE 19, 2019

There’s a speed dating game of sorts happening as pharmaceutical companies that have approved cancer immunotherapies are testing their medications in combination with experimental drugs in hopes of reaching more patients.

Study 61

Study Activity Develop Development 61

Xconomy

JULY 20, 2016

First came Inception Sciences , a holding company for spinning out biotech startups established by Versant Ventures and Peppi Prasit, the veteran San Diego drug developer. All of the company’s funding so far has come from Sofinnova Ventures, and Mike Powell, a Sofinnova general partner in San Francisco, is board chairman.

San Diego 40

San Diego Avalon Outsource Development Newsletter 40

Xconomy

FEBRUARY 14, 2020

Post-marketing studies aim to identify side effects not observed in the first three phases of testing. This week, results of such a study led to the market withdrawal of weight-loss pill lorcaserin (Belviq). But the post-marketing study revealed a higher incidence of.

Study 77

Study Marketing San Diego Blogging 77

Xconomy

FEBRUARY 22, 2017

PMV Pharmaceuticals is the latest startup to load up with cash in an attempt to home in on one of the toughest targets in cancer biology: the tumor suppressor protein known as p53. The new cash will help PMV push into human clinical studies, though in its statement the startup didn’t say when those studies might begin.

Study 67

Study Startup Funding Capital 67

InfoChachkie

MAY 26, 2016

Given the stellar startup careers of non-college graduates like Zuckerberg, Ellison, Disney, Gates, Jobs, Branson and Dell, the answer to this question might surprise you. In each case, the students were glad they remained in school and snagged their diploma before launching their startups. . In sports, outliers generate headlines.

Entrepreneur 150

Entrepreneur Case Study Education Seed Funding 150

Xconomy

JANUARY 9, 2019

Beta Bionics, a startup developing a medical device that monitors and manages blood sugar levels in diabetes patients, has closed $63 million to back late-stage clinical tests of its AI-powered technology. The cash tops off a Series B round of funding announced last year. Beta Bionics’s device is designed to mimic the role of.

Study 87

Study Design Capital Startup 87

Xconomy

SEPTEMBER 2, 2016

Nobel Prize winner Roger Tsien, a UC San Diego chemist, passed away in Oregon this week. As the San Diego Union Tribune reported in 2013, Tsien (pictured) was also unafraid to shine the spotlight on what he considered suspect scientific approaches, even when espoused by legends like DNA co-discoverer James Watson.

News 57

News San Diego Journal Technical Review 57

Xconomy

JUNE 13, 2019

The new Series B round will give San Francisco-based BlackThorn—a startup spun out of the Scripps Research Institute in 2013—the backing to run human tests of two experimental treatments. The other, for autism, could start a Phase 1 study in 2020. Those plans.

Tool 78

Tool Study Research Startup 78

Xconomy

NOVEMBER 7, 2016

Up until this point, studies of an experimental drug from Biogen and Ionis Pharmaceuticals had focused on patients with the most severe form of a rare, potentially deadly genetic disorder called spinal muscular atrophy. Biogen enrolled 126 patients in the study; 84 got nusinersen while 42 got a placebo.

Help 97

Help Study Research Statistics 97

Xconomy

AUGUST 17, 2016

Avalon Ventures founded Avelas, and has housed the startup with other Avalon biotech startups at its COI Pharmaceuticals R&D facility in San Diego. The first-in-human trials of AVB-620 began last year at UC San Diego’s Moores Cancer Center. Carmine Stengone.

Avalon 40

Avalon San Diego Study Invest 40

Xconomy

MARCH 27, 2020

Fallout from the spread of COVID-19 infections led several companies to declare this week that they would stop enrolling patients in clinical trials or postpone studies that have not yet started. Pfizer (NYSE: PFE ) is delaying new patient recruitment for three weeks.

Study 95

Study Resource Sites San Diego 95

Xconomy

MARCH 2, 2020

The company’s lead drug, ORIC-101, is under evaluation in Phase 1b studies in combination with enzalutamide (Xtandi) in prostate cancer and. ORIC is an acronym for “overcoming resistance in cancer.” Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Study 90

Study Research Funding Marketing 90

Xconomy

MAY 22, 2020

As the nation started to reopen this week following two months of closed businesses and stay-at-home orders, public health officials and economists cautioned that society won’t truly return to anything resembling a pre-pandemic normal without a COVID-19 vaccine. Furthermore, Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Study 80

Study Report San Diego Blogging 80